Adding a new drug to standard hormone therapy for metastatic breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether adding the drug capivasertib to standard hormone therapy works better for metastatic breast cancer that is HR positive and HER2 negative. It uses a blood test (ctDNA) to monitor response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced breast cancer (spread to other parts of the body or can't be removed with surgery).
- Your cancer is estrogen receptor positive (ER+) or progesterone receptor positive (PR+) and HER2 negative.
- You have not had any prior treatment for metastatic breast cancer (except you may have had hormone therapy or chemotherapy in the past for early-stage disease).
- You are generally healthy (able to do daily activities with little or no help).
- You have adequate organ function (kidney, liver, etc.) as determined by blood tests.
- You must be willing to give blood samples for ctDNA testing and start treatment with a combination of drugs (capivasertib plus standard hormone therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug called capivasertib combined with standard hormone therapy for people with advanced breast cancer that is HR-positive and HER2-negative. It is for those whose cancer has progressed on previous hormone therapy and who have a specific gene change (PIK3CA, AKT1, or PTEN).
This trial tests adding capivasertib to fulvestrant for women with a certain type of breast cancer (invasive lobular carcinoma) that is hormone-receptor positive and has a high risk of coming back. The treatment is given before surgery to see if it works better than fulvestrant alone.
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
This trial tests whether giving a combination of the drugs capivasertib and fulvestrant, along with medicines to prevent rash and diarrhea, can help treat hormone receptor-positive breast cancer that has a PIK3CA, AKT1, or PTEN change. It's for people whose cancer has spread or is locally advanced and can't be removed with surgery.
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Hear when a new HR Positive/HER-2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.